Incannex Healthcare: Developing cannabinoid treatment for obstructive sleep apnoea

Incannex Healthcare (Nasdaq: IXHL, ASX: IHL) is an Australian biotech specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies.

Motivated to find new treatments to alleviate patients’ suffering across a range of chronic medical conditions, from 2014, the company began a swathe of research projects to inform its development of pharmacotherapy programmes to meet unmet patients’ needs.

In February 2022, Incannex achieved its Nasdaq listing as the company promoted six lead assets in its development pipeline: treatments for obstructive sleep apnoea (OSA), traumatic brain injury, inflammatory lung conditions, inflammatory bowel disease, rheumatoid arthritis and generalised anxiety disorder.

Incannex has 28 clinical programmes in progress and holds one of the world’s largest portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes.

Incannex’s most advanced clinical asset, IHL-42X, being developed for the treatment of OSA, will see bioavailability and bioequivalence studies roll out in 2023.